Palatin Technologies Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Palatin Technologies, Inc. was founded in 1986 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Carl Spana |
Contact Details
Address: 103 Carnegie Center Drive Princeton, Delaware 08852 United States | |
| Phone | 609 495 2200 |
| Website | palatin.com |
Stock Details
| Ticker Symbol | PTNT |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Burns McClellan | Vice President of Investor Relations |
| Stephen A. Slusher Esq. | Chief Legal Officer |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer |
| James E. Hattersley B.A., M.S. | Senior Vice President of Business Development |
| John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Robert Jordan | Senior Vice President of Program Operations |